Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ central nervous system events (e.g. confusion,… compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ gastrointestinal effects (e.g. constipation,… compared with placebo (very low certainty).
1 finding from 1 review
GABA analogue VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Montelukast Duo score (0 to 81) and VAS (0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Sertraline VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Lidocaine Itch relief · uraemic pruritus
1 finding from 1 review
Sodium thalidomide Itch relief · uraemic pruritus
1 finding from 1 review
Doxepin Itch relief · uraemic pruritus
1 finding from 1 review
Ondansetron VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Kappa‐opioid agonist VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Mu‐opioid antagonist VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Nalbuphine VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Cromolyn VAS(0 to 10 cm) · uraemic pruritus
1 finding from 1 review
Nicotinamide VAS(0 to 5 cm) · uraemic pruritus
1 finding from 1 review
EPO Duo score(0 to 40) · uraemic pruritus
1 finding from 1 review
Cholestyramine 0 to 3 severity scale · uraemic pruritus
1 finding from 1 review
Smoking cessation · young people
It is very uncertain whether pharmacological interventions changes bupropion vs placebo Smoking cessation compared with placebo (very low certainty).
3 findings from 1 review
RR 1.49 [0.55, 4.02]
1 study · 207 participants
Very low
RR 1.05 [0.41, 2.69]
1 study · 211 participants
Very low
RR 1.11 [0.48, 2.58]
2 studies · 385 participants
Very low
Adverse events (control ‐ placebo) · young people
3 findings from 1 review
no estimate extracted
1 study · 207 participants
Very low
no estimate extracted
1 study · 211 participants
Very low
no estimate extracted
2 studies · 385 participants
Very low
Comparisons and outcomes · young people
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found